Vericel Co. (NASDAQ:VCEL - Get Free Report) CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares in the company, valued at approximately $11,902,662.66. This represents a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Vericel Trading Down 0.0 %
Shares of Vericel stock opened at $45.38 on Friday. The company's 50-day moving average price is $55.59 and its two-hundred day moving average price is $51.86. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The stock has a market cap of $2.27 billion, a PE ratio of 756.46 and a beta of 1.78.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on VCEL. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. BTIG Research lifted their price objective on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Truist Financial restated a "buy" rating and set a $61.00 price objective (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Finally, Stephens reiterated an "overweight" rating and issued a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and an average price target of $62.29.
View Our Latest Research Report on Vericel
Institutional Trading of Vericel
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock worth $24,837,000 after buying an additional 400,667 shares during the period. Stifel Financial Corp raised its holdings in Vericel by 40.0% during the 3rd quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock worth $1,186,000 after buying an additional 8,020 shares during the period. Geode Capital Management LLC raised its holdings in Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock worth $48,768,000 after buying an additional 9,613 shares during the period. Louisiana State Employees Retirement System raised its holdings in Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock worth $1,312,000 after buying an additional 200 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Vericel during the 3rd quarter worth about $563,000.
Vericel Company Profile
(
Get Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
